Edith C. Bougouma
YOU?
Author Swipe
View article: Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials Open
The European Commission Framework 7 and The European & Developing Countries Clinical Trials Partnership.
View article: Evaluating artesunate monotherapy and dihydroartemisinin-piperaquine as potential antimalarial options for prevaccination radical cures during future malaria vaccine field efficacy trials
Evaluating artesunate monotherapy and dihydroartemisinin-piperaquine as potential antimalarial options for prevaccination radical cures during future malaria vaccine field efficacy trials Open
NCT04601714.
View article: Antibody Response to <i>Plasmodium falciparum</i> Novel Synthetic Peptides and Protection Against Malaria in a Malaria Endemic Area in Burkina Faso
Antibody Response to <i>Plasmodium falciparum</i> Novel Synthetic Peptides and Protection Against Malaria in a Malaria Endemic Area in Burkina Faso Open
View article: Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36/CpG in 5–10-Year-Old Burkinabe Children Naturally Exposed to Malaria
Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36/CpG in 5–10-Year-Old Burkinabe Children Naturally Exposed to Malaria Open
Information on the dynamics and decline/persistence of antibody titres is important in vaccine development. A recent vaccine trial in malaria-exposed, healthy African adults and children living in a malaria hyperendemic and seasonal area (…
View article: A randomized first-in-human phase I trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults
A randomized first-in-human phase I trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults Open
BACKGROUNDMalaria transmission-blocking vaccines aim to interrupt the transmission of malaria from one person to another.METHODSThe candidates R0.6C and ProC6C share the 6C domain of the Plasmodium falciparum sexual-stage antigen Pfs48/45.…
View article: PA-435 Long-term immune response in children vaccinated with BK-SE36/CpG blood stage malaria candidate vaccine in a malaria hyperendemic and seasonal area of Burkina Faso
PA-435 Long-term immune response in children vaccinated with BK-SE36/CpG blood stage malaria candidate vaccine in a malaria hyperendemic and seasonal area of Burkina Faso Open
Background BK-SE36/CpG is a lyophilized formulation of recombinant Plasmodium falciparum serine repeat antigen 5 adsorbed to aluminium hydroxide gel and reconstituted with the TLR9 adjuvant, CpG-ODN (K3). In the primary study in malaria-ex…
View article: PA-463 Phase 1b randomized, controlled, double-blinded, age de-escalation trial to evaluate the safety, reactogenicity and immunogenicity of BK-SE36/CpG malaria vaccine in Burkinabe healthy adults and children
PA-463 Phase 1b randomized, controlled, double-blinded, age de-escalation trial to evaluate the safety, reactogenicity and immunogenicity of BK-SE36/CpG malaria vaccine in Burkinabe healthy adults and children Open
Background BK-SE36/CpG is a recombinant Plasmodium falciparum vaccine candidate targeting blood-stage parasites. The P. falciparum SE36 protein was expressed in E. coli, adsorbed to aluminium hydroxide gel, and reconstituted with CpG adjuv…
View article: Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial
Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial Open
Background BK-SE36/CpG is a recombinant blood-stage malaria vaccine candidate based on the N-terminal Plasmodium falciparum serine repeat antigen5 (SE36), adsorbed to aluminium hydroxide gel and reconstituted, prior to administration, with…
View article: Plasmodium falciparum infection coinciding with the malaria vaccine candidate BK-SE36 administration interferes with the immune responses in Burkinabe children
Plasmodium falciparum infection coinciding with the malaria vaccine candidate BK-SE36 administration interferes with the immune responses in Burkinabe children Open
Background A vaccine targeting the erythrocyte stages of Plasmodium falciparum could play a role in preventing clinical disease. BK-SE36 is a promising malaria vaccine candidate that has shown a good safety profile and immunological respon…
View article: African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody response to BK-SE36 vaccination
African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody response to BK-SE36 vaccination Open
BK-SE36, based on Plasmodium falciparum serine repeat antigen 5 (SERA5), is a blood-stage malaria vaccine candidate currently being evaluated in clinical trials. Phase 1 trials in Uganda and Burkina Faso have demonstrated promising safety …
View article: A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria
A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria Open
A highly effective malaria vaccine remains elusive despite decades of research. Plasmodium falciparum sporozoite vaccine (PfSPZ Vaccine), a metabolically active, nonreplicating, whole parasite vaccine demonstrated safety and vaccine effica…
View article: Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children
Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children Open
Background A blood-stage vaccine targeting the erythrocytic-stages of the malaria parasite Plasmodium falciparum could play a role to protect against clinical disease. Antibodies against the P. falciparum serine repeat antigen 5 (SE47 and …
View article: The ABO Blood Group System and <i>Plasmodium falciparum</i> (<i>Pf </i>) Infection in Three Ethnic Groups Living in the Stable and Seasonal Malaria Transmission Areas of Burkina Faso (BF)
The ABO Blood Group System and <i>Plasmodium falciparum</i> (<i>Pf </i>) Infection in Three Ethnic Groups Living in the Stable and Seasonal Malaria Transmission Areas of Burkina Faso (BF) Open
Genetic factors, including red blood cell polymorphisms, influence the severity of disease due to infection with Plasmodium falciparum (Pf). Studies show that these genetic factors associated with malaria susceptibility or resistance vary …
View article: Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial
Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial Open
TCV can be safely co-administered with MR and YF vaccines to children at the 9-month vaccination visit.
View article: A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria
A randomized, double-blind, phase 2b study to investigate the efficacy, safety, tolerability and pharmacokinetics of a single-dose regimen of ferroquine with artefenomel in adults and children with uncomplicated Plasmodium falciparum malaria Open
View article: G6PD Polymorphisms and Hemolysis After Antimalarial Treatment With Low Single-Dose Primaquine: A Pooled Analysis of Six African Clinical Trials
G6PD Polymorphisms and Hemolysis After Antimalarial Treatment With Low Single-Dose Primaquine: A Pooled Analysis of Six African Clinical Trials Open
Primaquine (PQ) is an antimalarial drug with the potential to reduce malaria transmission due to its capacity to clear mature Plasmodium falciparum gametocytes in the human host. However, the large-scale roll-out of PQ has to be counterbal…
View article: Inherited Disorders of Hemoglobin and <i>Plasmodium falciparum</i> Malaria
Inherited Disorders of Hemoglobin and <i>Plasmodium falciparum</i> Malaria Open
An estimated 300,000 babies are born each year with severe Inherited Disorders of Hemoglobin (IDH). Despite major advances in the understanding of the molecular pathology, control, and management of the IDH thousands of infants and childre…
View article: Experimental Study: The Relationship between Plasmodium falciparum Gametocyte Carriage and Mosquitoes Infectiousness in Two Sympatric Ethnic Groups in Burkina Faso
Experimental Study: The Relationship between Plasmodium falciparum Gametocyte Carriage and Mosquitoes Infectiousness in Two Sympatric Ethnic Groups in Burkina Faso Open
Aims: The lower susceptibility of the Fulani to malaria compared to Mossi was previously described in Burkina Faso in West Africa. The mature gametocyte stage of Plasmodium falciparum is known to be the only stage capable of infecting the …
View article: Insights into malaria susceptibility using genome-wide data on 17,000 individuals from Africa, Asia and Oceania
Insights into malaria susceptibility using genome-wide data on 17,000 individuals from Africa, Asia and Oceania Open
View article: Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers
Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers Open
Background Improvements in malaria control have stalled recently and new tools are needed. The R21 vaccine is comprised of the malaria circumsporozoite protein fused to hepatitis B surface antigen (HBsAg). It forms particles that lack the …
View article: Abnormalities of Hemoglobin and Glucose-6-Phosphate-Dehydrogenase Deficiency in Children with Uncomplicated Malaria and Living in Banfora and Saponé, Two Different Malaria Setting of Burkina Faso
Abnormalities of Hemoglobin and Glucose-6-Phosphate-Dehydrogenase Deficiency in Children with Uncomplicated Malaria and Living in Banfora and Saponé, Two Different Malaria Setting of Burkina Faso Open
Aims: The aim of this study is to assess the prevalence of hemoglobin abnormalities and G6PD deficiency and their respective influence on anemia occurring in less than five years old children with clinical P. falciparum malaria living in B…
View article: OC 8552 EFFICACY OF THE CHAD63-MVC ME-TRAP VECTORED MALARIA VACCINE CANDIDATE IN 5–17 MONTHS OLD INFANTS AND CHILDREN IN BURKINA FASO
OC 8552 EFFICACY OF THE CHAD63-MVC ME-TRAP VECTORED MALARIA VACCINE CANDIDATE IN 5–17 MONTHS OLD INFANTS AND CHILDREN IN BURKINA FASO Open
Background Heterologous prime-boost immunisation with chimpanzee adenovirus 63 (ChAd63) and Modified Vaccinia Virus Ankara (MVA)-vectored vaccines is a strategy previously shown to provide substantial protective efficacy against P. falcipa…
View article: OC 8546 SAFETY AND IMMUNOGENICITY OF THE MALARIA VACCINE CANDIDATE BK-SE36 IN YOUNG CHILDREN LIVING IN BURKINA FASO
OC 8546 SAFETY AND IMMUNOGENICITY OF THE MALARIA VACCINE CANDIDATE BK-SE36 IN YOUNG CHILDREN LIVING IN BURKINA FASO Open
Background The malaria blood stage vaccine candidate SE-36 is based on the serine repeat antigen of Plasmodium falciparum . Epidemiological studies have shown that antibodies against SE36 correlate with lower parasitaemia in Solomon Island…
View article: Bead-based assays to simultaneously detect multiple human inherited blood disorders associated with malaria
Bead-based assays to simultaneously detect multiple human inherited blood disorders associated with malaria Open
View article: Relationship between human genetic factors and Plasmodium falciparum genetic diversity of msp1, msp2 and glurp in a malaria endemic area of Burkina Faso
Relationship between human genetic factors and Plasmodium falciparum genetic diversity of msp1, msp2 and glurp in a malaria endemic area of Burkina Faso Open
Human genetic factors mechanisms are known to protect against malaria.However, the mechanism underlying the influence of human genetic variation on Plasmodium falciparum (P.falciparum) genetic diversity is still a research purpose.The aim …
View article: Seroreactivity of Populations Living in Endemic Area of Burkina Faso to Plasmodium falciparum Alpha-Helical Coiled Coil Proteins Motifs by Protein Microarray
Seroreactivity of Populations Living in Endemic Area of Burkina Faso to Plasmodium falciparum Alpha-Helical Coiled Coil Proteins Motifs by Protein Microarray Open
The naturally acquired immunity is one of the models of immunity that is exploited for malaria antigens discovery. We have used multiplex protein microarrays of 92 P. falciparum alpha-helical coiled coil protein motifs to screen plasma sam…
View article: MOESM2 of Bead-based assays to simultaneously detect multiple human inherited blood disorders associated with malaria
MOESM2 of Bead-based assays to simultaneously detect multiple human inherited blood disorders associated with malaria Open
Additional file 2: Table S6. G6PD G202A & A376G genotyping comparison. The MagPix genotyping calls were compared to data generated by TaqMan OpenArray and KASP PCR-based genotyping. Wild type calls are 202G and 376A, A- calls are 202A and …
View article: First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children Open
ClinicalTrials.gov NCT01635647. Pactr.org PACTR201208000404131.
View article: Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial
Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial Open
View article: Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study
Human candidate gene polymorphisms and risk of severe malaria in children in Kilifi, Kenya: a case-control association study Open